Shares of Amicus Therapeutics (FOLD) were down over 26% in extended trading on Monday as the FDA has ruled that accelerated approval of Migalastat for Fabry Disease is not possible based on existing data related to GL-3 reduction, a key biomarker of disease.
from RTT - Biotech http://ift.tt/2gAGFpx
via IFTTT
No comments:
Post a Comment